SCHEDULE: K2 HealthVentures Takes 6.6% Stake in Neumora

K2 HealthVentures Equity Trust LLC and its managing members have disclosed a 6.6% beneficial ownership in Neumora Therapeutics, Inc. common stock.

Summary

• K2 HealthVentures Equity Trust LLC, along with its managing members Parag Shah and Anup Arora, have reported beneficial ownership of 11,397,310 shares of Neumora Therapeutics, Inc. common stock.
• This ownership represents approximately 6.6% of Neumora Therapeutics' outstanding common stock.
• The shares are acquirable upon conversion of up to $10,000,000 of outstanding principal from debt obligations owed by Neumora Therapeutics to K2 HealthVentures Equity Trust LLC.
• The conversion price is set at the lesser of $0.8774 per share or the lowest effective price per share of Neumora Therapeutics' next equity financing.
• For the purpose of this filing, a conversion price of $0.8774 per share was assumed to calculate the number of beneficially owned shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership resulting from a debt conversion. It does not contain information that would significantly sway sentiment positively or negatively regarding the company's operational performance, but rather details a change in its capital structure and ownership.

Positives

• K2 HealthVentures Equity Trust LLC has secured a significant equity stake in Neumora Therapeutics, providing potential upside from future company growth.
• The conversion mechanism provides K2 HealthVentures with flexibility regarding the conversion price, potentially benefiting from a lower price in a future equity financing.

Negatives

• The conversion of debt into equity could lead to dilution for existing Neumora Therapeutics shareholders.
• The conversion price being tied to the 'lowest effective price per share of the Issuer's next equity financing' introduces uncertainty and could result in conversion at a lower valuation, increasing dilution.

Risks

• Potential dilution of existing shareholders' equity due to the conversion of debt into common stock.
• Uncertainty regarding the future conversion price, which is dependent on the terms of Neumora Therapeutics' next equity financing.
• The beneficial ownership is based on the right to acquire shares, not direct ownership, introducing a step before full equity realization.

Future Outlook

The filing indicates that the conversion price for the debt is tied to the 'lowest effective price per share of the Issuer's next equity financing,' suggesting that Neumora Therapeutics may pursue additional equity financing in the future.

Industry Context

This filing reflects a common financing strategy in the biotechnology and pharmaceutical sectors where debt instruments include conversion features, allowing lenders to participate in potential equity upside. Such arrangements are often used by companies like Neumora Therapeutics, which may require significant capital for research and development, to secure funding while offering investors a pathway to equity ownership.

Comparison to Industry Standards

• The conversion of debt to equity is a standard financing mechanism, particularly for growth-stage biotech companies like Neumora Therapeutics, which often rely on a mix of debt and equity to fund their operations and clinical trials.
• The 6.6% stake acquired by K2 HealthVentures is a notable position, indicating a significant investment by a specialized healthcare venture firm, comparable to other strategic investments seen in the sector where venture capital or debt providers take substantial equity positions.

Related Party Transactions

• The transaction involves the conversion rights of debt held by K2 HealthVentures Equity Trust LLC, a significant investor, into equity of Neumora Therapeutics, Inc. This represents a direct dealing between the issuer and a substantial debt holder.

Stakeholder Impact

• Shareholders: Potential for dilution of existing equity holdings if the debt is converted into new shares, especially if the conversion occurs at a lower price per share during a future equity financing.
• Creditors: The conversion of debt to equity reduces the company's outstanding debt obligations to K2 HealthVentures, potentially improving the company's debt-to-equity ratio.

Next Steps

• K2 HealthVentures Equity Trust LLC has the right to convert its $10,000,000 debt principal into common stock.
• Neumora Therapeutics, Inc. may proceed with a 'next equity financing' which could impact the final conversion price for K2 HealthVentures.

Key Dates

Keywords

Neumora Therapeutics, K2 HealthVentures, Beneficial Ownership, Schedule 13G, Debt Conversion, Equity Stake, Common Stock, Biotechnology, Pharmaceuticals, Investment